Open access
Open access
Powered by Google Translator Translator

Covid-19

Yes, relapses after Paxlovid happen — now what?

26 Apr, 2022 | 08:18h | UTC

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

 

Commentary on Twitter

 

Why does the Omicron variant largely spare olfactory function? implications for the pathogenesis of anosmia in COVID-19.

26 Apr, 2022 | 08:05h | UTC

Why does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in COVID-19 – The Journal of Infectious Diseases

 

Cohort Study: Effectiveness of homologous vs. heterologous booster doses for an inactivated SARS-CoV-2 vaccine.

26 Apr, 2022 | 08:06h | UTC

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study – The Lancet Global Health

Commentaries:

COVID-19 vaccine booster strategy: striving for best practice – The Lancet Global Health

Covid-19: Mix and match booster vaccination approach offers best protection, study reports – The BMJ

 

Commentary on Twitter

 

Cohort Study: COVID-19 vaccination during early pregnancy was not associated with increased risk of congenital fetal anomalies.

25 Apr, 2022 | 00:59h | UTC

Association of COVID-19 Vaccination During Early Pregnancy With Risk of Congenital Fetal Anomalies – JAMA Pediatrics

Commentaries:

COVID vaccine in early pregnancy not tied to birth defects – CIDRAP

No Sign That COVID Vaccine in Pregnancy Raises Birth Defect Risk – HealthDay

 

SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity.

25 Apr, 2022 | 00:56h | UTC

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Related Study:

Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open AND Commentaries: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services AND COVID-19 infection may offer similar immunity as vaccination – CIDRAP

 

Systematic Review: The performance of wearable sensors in the detection of SARS-CoV-2 infection.

25 Apr, 2022 | 00:55h | UTC

The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review – The Lancet Digital Health

 

Commentary on Twitter

Under a (CC BY 4.0) License

 

WHO recommends highly successful COVID-19 therapy (nirmatrelvir-ritonavir) and calls for wide geographical distribution and transparency from originator.

22 Apr, 2022 | 09:36h | UTC

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

See also:

A living WHO guideline on drugs for covid-19 – The BMJ

Therapeutics and COVID-19: living guideline – World Health Organization

Related:

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

 

Commentary on Twitter

 

Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries.

22 Apr, 2022 | 09:28h | UTC

Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries – The Lancet Public Health

News Release: Stricter COVID-19 measures associated with negative mental health effects and lower opinion of government’s pandemic response, new research suggests – The Lancet

Commentary: Stricter Pandemic Policies Took Toll on Mental Health — Women tended to be more affected than men – MedPage Today

 

RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.

21 Apr, 2022 | 10:29h | UTC

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 

Cohort study: COVID-19 infection granted patients strong and long-lasting protection from reinfection.

21 Apr, 2022 | 10:20h | UTC

News Release: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services

Original Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open

Commentary: COVID-19 infection may offer similar immunity as vaccination – CIDRAP

 

Commentary on Twitter

 

SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents.

21 Apr, 2022 | 10:23h | UTC

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Editorial: Communicating the Benefits of Vaccination in Light of Potential Risks

 

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel.

20 Apr, 2022 | 09:57h | UTC

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel – STAT

 

A nonrandomized controlled study found awake prone position (median of 4.2 hours per day) may not benefit hospitalized adults with Covid-19.

20 Apr, 2022 | 09:56h | UTC

Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial – JAMA Internal Medicine

Commentaries:

Prone Positioning for Nonintubated Patients With COVID-19—Potential Dangers of Extrapolation and Intermediate Outcome Variables – JAMA Internal Medicine

Study suggests worse outcomes for awake COVID patients in prone position – CIDRAP

Putting Hospitalized COVID Patients on Their Belly May Not Be a Good Idea After All – HealthDay

Related:

Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE) – The BMJ

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial – Critical Care

Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis – Critical Care Medicine

 

Commentary on Twitter (thread – click for more)

 

Video: Here’s what we know about COVID-19’s impact on the brain.

19 Apr, 2022 | 02:22h | UTC

Here’s what we know about COVID-19’s impact on the brain – Science

Related:

SARS-CoV-2 is associated with changes in brain structure in UK Biobank – Nature

Nervous system consequences of COVID-19 – Science

The COVID generation: how is the pandemic affecting kids’ brains? – Nature

Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis – Brain, Behavior, and Immunity

Assessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open

 

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial.

19 Apr, 2022 | 02:25h | UTC

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial – Reuters

 

Commentary on Twitter

 

M-A: Global prevalence of post COVID-19 condition or long COVID.

19 Apr, 2022 | 02:18h | UTC

Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review – The Journal of Infectious Diseases

Commentary: Global data reveal half may have long COVID 4 months on – CIDRAP

 

Commentary on Twitter (thread – click for more)

 

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease.

19 Apr, 2022 | 02:14h | UTC

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease – Open Forum Infectious Diseases

 

Commentary on Twitter

 

Review: Covid-19: virology, variants, and vaccines.

18 Apr, 2022 | 10:50h | UTC

Covid-19: virology, variants, and vaccines – BMJ Medicine

 

Commentary on Twitter

 

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study.

18 Apr, 2022 | 10:52h | UTC

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study – CMAJ Open

Commentary: COVID-19 household transmission is high, with children being a significant source of spread: study – CHEO

 

Commentary on Twitter (thread – click for more)

 

EBM Analysis: Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomized studies.

18 Apr, 2022 | 10:48h | UTC

Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies – BMJ Evidence-Based Medicine

 

Commentary on Twitter

 

Cohort Study: Changes in the incidence of retinal vascular occlusions after COVID-19 diagnosis.

18 Apr, 2022 | 10:34h | UTC

Changes in the Incidence of Retinal Vascular Occlusions After COVID-19 Diagnosis – JAMA Ophthalmology

Commentaries:

COVID-19 Diagnosis and Incidence of Retinal Thromboembolism – JAMA Ophthalmology

Threatening Eye Condition Rare After COVID Infection – HealthDay

 

M-A: Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination.

18 Apr, 2022 | 10:32h | UTC

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Commentaries:

Myopericarditis following COVID-19 vaccination is rare, finds international study – The Lancet

Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented – The Lancet Respiratory Medicine

Study explores myopericarditis incidence and COVID-19 vaccination – News Medical

 

Commentary on Twitter

 

A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes.

14 Apr, 2022 | 08:51h | UTC

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Related:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

Covid-19: What is the evidence for the antiviral molnupiravir?

14 Apr, 2022 | 08:47h | UTC

Covid-19: What is the evidence for the antiviral molnupiravir? – The BMJ

 

Study showed low rates of severe COVID-19 in children hospitalized with confirmed SARS-CoV-2 infection.

14 Apr, 2022 | 08:49h | UTC

Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England – Journal of Infection

Commentary: Severe COVID-19 extremely rare among children – News Medical

Related:

[Preprint] Risk of Hospitalization, severe disease, and mortality due to COVID-19 in children with SARS-CoV-2 infection in Germany – “overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000”.

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

COVID-19 disease severity in children infected with the Omicron variant.

Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year.

Study identifies risk factors for severe CoviD-19 in children.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

International study identifies predictors of severe outcomes in children with COVID-19.

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.